Evidence map›Paper›PMID 41824917›Full record

ArticleChemMedChem2026

Modulation of Tau Protein Neurotoxic Hallmarks by Novel σ

Antonino N Fallica, Carla Barbaraci, M Carmen Ruiz-Cantero, Arianna Scarlatti, Alessandro Coco, Giorgia Giordano, Alfonsina La Mantia, Orazio Prezzavento, Antonio Di Stefano, Ivana Cacciatore and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ChemMedChem, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Antonino N FallicaDepartment of Drug and Health Sciences, University of Catania, Catania, Italy.ORCID https://orcid.org/0000-0003-1899-8414
Carla BarbaraciDepartment of Drug and Health Sciences, University of Catania, Catania, Italy.ORCID https://orcid.org/0000-0002-6155-6702
M Carmen Ruiz-CanteroLaboratori de Química Farmacèutica, Facultat de Farmàcia i Ciències de l'Alimentació, Universitat de Barcelona, Barcelona, Spain.ORCID https://orcid.org/0000-0001-6968-0946
Arianna ScarlattiLaboratorio di Biologia Bio@SNS, Scuola Normale Superiore di Pisa, Pisa, Italy.ORCID https://orcid.org/0009-0000-8407-1671
Alessandro CocoDepartment of Drug and Health Sciences, University of Catania, Catania, Italy.
Giorgia GiordanoDepartment of Drug and Health Sciences, University of Catania, Catania, Italy.
Alfonsina La MantiaDepartment of Drug and Health Sciences, University of Catania, Catania, Italy.
Orazio PrezzaventoDepartment of Drug and Health Sciences, University of Catania, Catania, Italy.
Antonio Di StefanoDepartment of Pharmacy, University "G. d'Annunzio" of Chieti-Pescara, Chieti Scalo, Italy.ORCID https://orcid.org/0000-0002-3042-2234
Ivana CacciatoreDepartment of Pharmacy, University "G. d'Annunzio" of Chieti-Pescara, Chieti Scalo, Italy.ORCID https://orcid.org/0000-0001-6253-0443
Giacomo SianoItalian National Research Council (CNR), Institute of Neuroscience, Pisa, Italy.ORCID https://orcid.org/0000-0003-4320-5631
Antonino CattaneoLaboratorio di Biologia Bio@SNS, Scuola Normale Superiore di Pisa, Pisa, Italy.
Lorella PasquinucciDepartment of Drug and Health Sciences, University of Catania, Catania, Italy.
Enrique J CobosDepartment of Pharmacology and Neurosciences Institute (Biomedical Research Center) and Biosanitary Research Institute ibs.GRANADA, University of Granada, Granada, Spain.
Cristina Di PrimioItalian National Research Council (CNR), Institute of Neuroscience, Pisa, Italy.ORCID https://orcid.org/0000-0003-2140-3696
Emanuele AmataDepartment of Drug and Health Sciences, University of Catania, Catania, Italy.ORCID https://orcid.org/0000-0002-4750-3479
Agostino MarrazzoDepartment of Drug and Health Sciences, University of Catania, Catania, Italy.ORCID https://orcid.org/0000-0002-8728-8857

Funding

Ministero dell'Università e della Ricerca 2022HRS4YBMinistero dell'Università e della Ricerca 2022Z3BBPEMinistero dell'Università e della Ricerca P20224L3NK
6 · The paper itself

Abstract

Neurodegenerative diseases, like Alzheimer's disease (AD), are characterized by the accumulation of tau aggregates, leading to neuronal dysfunction and cognitive decline. This study explores the development of dual-acting compounds combining sigma-1 receptor (σ

Indexed as

Histone Deacetylase InhibitorsNeuroprotective AgentsReceptors, sigmatau ProteinsAnimalsDose-Response Relationship, DrugHistone DeacetylasesHumansMolecular StructureRatsSigma-1 ReceptorStructure-Activity RelationshipHistone Deacetylase InhibitorsHistone DeacetylasesNeuroprotective AgentsReceptors, sigmaSigma-1 Receptortau Proteinsdual‐acting compoundsHDAC inhibitorsneurodegenerative diseasesneuroprotectionphenylbutyric acidsigma receptors (σRs)tau proteinvalproic acidσ1R agonists

Identifiers

PMID41824917
PMCPMC12987640

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.